Multimarker strategy for short-term risk assessment in patients with dyspnea in the emergency department: The marked (multi marker emergency dyspnea)-risk score

L.W. Eurlings, S. van Wijk, R. van Kimmenade, A. Osinski, L. van Helmond, M. Vallinga, H.J. Crijns, M.P. van Dieijen-Visser, H.P. Brunner La Rocca, Y.M. Pinto

Research output: Contribution to journalArticleAcademicpeer-review

19 Citations (Scopus)

Abstract

OBJECTIVES: The study aim was to determine the prognostic value of a multimarker strategy for risk-assessment in patients presenting to the emergency department (ED) with dyspnea. BACKGROUND: Combining biomarkers with different pathophysiological backgrounds may improve risk stratification in dyspneic patients in the ED. METHODS: The study prospectively investigated the prognostic value of the biomarkers N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), Cystatin-C (Cys-C), high-sensitivity C-reactive protein (hs-CRP), and Galectin-3 (Gal-3) for 90-day mortality in 603 patients presenting to the ED with dyspnea as primary complaint. RESULTS: hs-CRP, hs-cTnT, Cyst-C, and NT-proBNP were independent predictors of 90-day mortality. The number of elevated biomarkers was highly associated with outcome (odds ratio: 2.94 per biomarker, 95% confidence interval [CI]: 2.29 to 3.78, p < 0.001). A multimarker approach had incremental value beyond a single-marker approach. Our multimarker emergency dyspnea-risk score (MARKED-risk score) incorporating age >/=75 years, systolic blood pressure <110 mm Hg, history of heart failure, dyspnea New York Heart Association functional class IV, hs-cTnT >/=0.04 mug/l, hs-CRP >/=25 mg/l, and Cys-C >/=1.125 mg/l had excellent prognostic performance (area under the curve: 0.85, 95% CI: 0.81 to 0.89), was robust in internal validation analyses and could identify patients with very low (<3 points), intermediate (>/=3, <5 points), and high risk (>/=5 points) of 90-day mortality (2%, 14%, and 44% respectively; p < 0.001). CONCLUSIONS: A multimarker strategy provided superior risk stratification beyond any single-marker approach. The MARKED-risk score that incorporates hs-cTnT, hs-CRP, and Cys-C along with clinical risk factors accurately identifies patients with very low, intermediate, and high risk.
Original languageEnglish
Pages (from-to)1668-1677
Number of pages10
JournalJournal of the American College of Cardiology
Volume60
Issue number17
DOIs
Publication statusPublished - 23 Oct 2012

Keywords

  • biomarkers
  • Cystatin-C
  • dyspnea
  • Galectin-3
  • heart failure
  • high-sensitivity C-reactive protein
  • high-sensitivity cardiac troponin T
  • N-terminal pro-BNP
  • prognosis
  • ACUTE HEART-FAILURE
  • C-REACTIVE PROTEIN
  • BRAIN NATRIURETIC PEPTIDE
  • CARDIAC TROPONIN-T
  • LOGISTIC-REGRESSION ANALYSIS
  • ACUTE PULMONARY-EMBOLISM
  • PROGNOSTIC VALUE
  • CYSTATIN-C
  • HIGH-SENSITIVITY
  • ATRIAL-FIBRILLATION

Cite this